Press release
U.S. Radiopharmaceuticals Market to Reach USD 2.36 Billion by 2033, Growing at 6.3% CAGR Driven by Advances in Nuclear Medicine and Theranostics
U.S. Radiopharmaceuticals Market
The increasing need for early diagnosis and personalized therapies further accelerates adoption across oncology, neurology, and cardiology applications. Aging populations, expanding healthcare access, and ongoing R&D investments in isotope production and radiotracer innovation continue to shape the industry. The launch of advanced manufacturing facilities, such as NorthStar Medical Radioisotopes' multi-isotope Dose Manufacturing Center in Beloit, Wisconsin, underscores the U.S. commitment to expanding domestic production capacity for key isotopes like Ac-225 and Lu-177, critical for high-quality patient care and nuclear medicine innovation.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/radiopharmaceuticals-market?Onkar
Key Highlights from the Report
➤ U.S. radiopharmaceuticals market estimated to reach USD 2.36 billion by 2033, growing at 6.3% CAGR from 2025 to 2033.
➤ Increasing cancer and cardiovascular disease prevalence drives demand for precision diagnostics and therapies.
➤ Expansion of theranostic applications integrating diagnosis and treatment enhances market growth.
➤ Artificial intelligence accelerates imaging analysis and radiopharmaceutical compound development.
➤ The Northeast region leads the market due to strong research infrastructure and advanced healthcare facilities.
➤ Continuous government investment in nuclear medicine production capabilities ensures a reliable isotope supply chain.
Market Segmentation
The U.S. radiopharmaceuticals market is segmented by product type, application, and end-use sectors.
By Product Type:
Diagnostic nuclear medicine remains the dominant segment, leveraging PET and SPECT imaging agents such as Technetium-99m and Fluorine-18 for early disease detection. Advances in molecular imaging continue to bolster the accuracy of diagnostic techniques, supporting high adoption in hospitals and diagnostic centers. Therapeutic nuclear medicine is witnessing rapid advancements with isotopes like Lutetium-177 and Iodine-131 driving radiotherapy in oncology, particularly for prostate and thyroid cancers.
By Application:
Oncology leads the U.S. market with the highest market share, owing to the widespread use of oncological radiotracers like Fluorine-18 and Lutetium-177 in both imaging and therapy. Cardiology follows, supported by the use of Technetium-99m in the assessment of coronary artery diseases and myocardial perfusion. Neurology and endocrinology are also contributing significantly with increasing diagnostic demand for Alzheimer's and thyroid disorders.
By End Use:
Hospitals and clinics form the largest end-use segment, as these facilities deploy radiopharmaceuticals in both diagnosis and treatment. Diagnostic centers are also witnessing growing use of PET and SPECT imaging for early disease detection. Research institutes remain essential for clinical trials, radiochemistry innovations, and academic-industry collaborations advancing new radiotracers and theranostic therapies.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/radiopharmaceuticals-market?Onkar
Regional Insights
Northeast Region - Industry Leader:
The Northeast holds the highest market share driven by advanced medical infrastructure, large patient populations, and concentration of research universities. The presence of prominent cancer treatment centers and nuclear medicine research institutions underpins high adoption levels of PET and SPECT technologies.
Midwest Region - Emerging Innovation Hub:
The Midwest region benefits from expanding production capabilities and increasing awareness of radiopharmaceutical benefits. Facilities such as NorthStar's Wisconsin Dose Manufacturing Center position the region as a nucleus for isotope innovation and supply-chain support.
South and West Regions - Accelerating Growth:
The South demonstrates the fastest-growing demand, propelled by large patient pools, rising chronic disease rates, and investments in diagnostic imaging infrastructure. The West, home to major biotech hubs, drives next-generation innovation in personalized nuclear therapies and non-invasive imaging systems.
Market Dynamics
Market Drivers:
Rising prevalence of cancer and cardiovascular diseases, combined with expanding use of PET and SPECT imaging, continues to boost radiopharmaceutical demand. Ongoing advancements in isotope production, theranostic solutions, and government-funded infrastructure further strengthen market expansion.
Market Restraints:
High production costs, short half-lives of radioisotopes, and stringent regulatory approvals limit rapid adoption. Limited availability of technical expertise in nuclear medicine may also slow expansion across smaller healthcare settings.
Market Opportunities:
Emerging applications in theranostics, AI integration in imaging analysis, and innovations in targeted alpha therapy (TAT) create new growth pathways. R&D collaborations between academia, startups, and pharmaceutical companies are paving the way for breakthroughs in radiopharmaceutical development.
Purchase This Exclusive Report at Just USD 6382 Only: https://www.datamintelligence.com/buy-now-page?report=radiopharmaceuticals-market?Onkar
Reasons to Buy the Report
✔ Gain a comprehensive understanding of U.S. radiopharmaceutical market growth drivers and challenges.
✔ Identify emerging trends shaping the future of therapeutic and diagnostic nuclear medicine.
✔ Evaluate strategic investment prospects in theranostics and AI-powered applications.
✔ Analyze leading players' innovation pipelines and regional market performance.
✔ Access detailed segmentation data to inform healthcare strategy and industry positioning.
Frequently Asked Questions (FAQs)
◆ How big is the U.S. Radiopharmaceuticals Market, and what growth rate is expected by 2033?
◆ What key factors are driving radiopharmaceutical demand in oncology and cardiology?
◆ Which product segment dominates the U.S. radiopharmaceuticals industry?
◆ Which region is expected to lead the market through the forecast period?
◆ How are AI and theranostics transforming diagnostic and therapeutic applications in nuclear medicine?
Company Insights
Lantheus Holdings, Inc.
BWXT Medical (BWX Technologies)
Cardinal Health, Inc.
Eli Lilly and Company
GE HealthCare
Siemens Healthineers
Curium Pharma
Jubilant Radiopharma (Jubilant Pharmova Limited's U.S.)
Nordion (Sotera Health Division)
Advanced Accelerator Applications (Novartis)
Recent Developments:
May 2024 - Fannin Partners launched Radiomer Therapeutics with pre-seed funding to advance its Raptamer-based radiopharmaceutical therapy platform targeting cancers such as breast, lung, and colorectal.
April 2024 - Evergreen Theragnostics raised USD 26 million in funding to develop its theranostic pair EVG-321 and expand CDMO services for Ga-68 DOTATOC diagnostic kits.
February 2024 - RadioMedix and Orano Med received FDA Breakthrough Therapy Designation for AlphaMedixTM (212Pb-DOTAMTATE) in neuroendocrine tumor treatment.
Conclusion
The U.S. radiopharmaceuticals market is entering a transformative phase, fueled by the convergence of personalized medicine, theranostics, and artificial intelligence. With rapid advancements in isotope manufacturing, imaging precision, and targeted therapies, the industry is poised for steady growth. Government support for infrastructure, coupled with the expansion of nuclear medicine capabilities, continues to enhance diagnostic accuracy and therapeutic outcomes. As innovation accelerates, radiopharmaceuticals will remain integral to the next generation of patient-centered healthcare solutions in the United States.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release U.S. Radiopharmaceuticals Market to Reach USD 2.36 Billion by 2033, Growing at 6.3% CAGR Driven by Advances in Nuclear Medicine and Theranostics here
News-ID: 4246729 • Views: …
More Releases from DataM Intelligence
U.S. Food Flavors Market to Reach USD 6.1 Billion by 2033, Registering 5.2% CAGR …
The U.S. flavors market was valued at USD 3,887.7 million in 2024 and is projected to reach USD 6,108.4 million by 2033, growing at a CAGR of 5.2% during 2025-2033, according to DataM Intelligence. The market's growth is driven by surging demand for processed foods, global flavor innovation, and increasing consumer preference for natural, clean-label, and wellness-oriented products. Flavors continue to play a vital role in enhancing the sensory experience…
Europe Feed Premix Market to Reach USD 7.31 Billion by 2030, Growing at a 4.32% …
The Europe Feed Premix Market is estimated to grow from USD 5.92 billion in 2025 to USD 7.31 billion by 2030, registering a CAGR of 4.32% during the forecast period, according to DataM Intelligence. The market's growth is driven by increasing demand for nutrient-rich animal feed formulations, expanding livestock production, and a rising preference for high-quality, antibiotic-free animal products. Feed premixes-comprising essential vitamins, minerals, amino acids, and other additives-are vital…
North America Feed Phytogenics Market to Reach USD 500.6 Million by 2030, Growin …
The North America Feed Phytogenics Market is projected to grow from USD 383.10 million in 2025 to USD 500.60 million by 2030, at a CAGR of 5.5% during the forecast period, according to DataM Intelligence. The market is witnessing robust growth due to rising demand for high-quality animal-derived products and increasing regulatory restrictions on antibiotics in livestock production. As a result, plant-based feed solutions have gained widespread adoption for improving…
U.S. Biodiesel Market to Reach USD 23.7 Billion by 2033, Growing at 4.81% CAGR D …
The United States biodiesel market size was valued at USD 15.2 billion in 2024 and is projected to reach USD 23.7 billion by 2033, registering a CAGR of 4.81% between 2025 and 2033, according to DataM Intelligence. The country's growing focus on decarbonization, sustainable fuel adoption, and circular energy systems continues to drive market expansion. Supported by strong production growth, favorable policy frameworks, and the rise in renewable energy consumption,…
More Releases for Radiopharma
Nuclear Pharmacy Market Future Business Opportunities 2025-2032 | Curium Pharma, …
The Latest study titled Nuclear Pharmacy Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the report…
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and St …
Actinium's Chief Medical Officer, said, "In addition to demonstrating unprecedented 100% access to BMT in Iomab-B treated patients with active r/r AML and achieving the primary endpoint of dCR with high statistical significance, we are excited by the compelling outcomes in patients with a TP53 mutation in the SIERRA trial. We look forward to returning to EBMT and once again highlighting the positive results from the Phase 3 SIERRA trial…
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma A …
Biotech Stocks Taking Centerstage
As the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium-225 (Ac-225), are gaining prominence for their targeted approach to cancer treatment. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate…
2030 Projections: Radiopharmaceutical Synthesizers Market to Deliver Dynamic Pro …
The Radiopharmaceutical Synthesizers Market Research Report 2023-2030 provides in-depth information on market trends, market capacity, industry size, growth factors, share, innovations, competitive environment, business problems, and more. This report's historical data confirms demand growth on a global, national, and regional scale. The studies on the global industry cover everything from comprehensive research to market size and forecasting to dynamics, growth factors, prospects, and hazards, as well as vendor knowledge. The…
Automated Radiosynthesis Modules Market Strategic Assessment & SWOT Analysis 202 …
An Informative report titled as Global Automated Radiosynthesis Modules Market has recently been published by Report Consultant to its online repository. This statistical data offers an in-depth analysis by considering several segments, such as type, size, technology and applications. Different exploratory techniques such as, qualitative and quantitative analysis have been used to give data accurately. For better understanding of the customers, it uses effective graphical presentation techniques, such as graphs,…
Cyclotron Market Growth Opportunities Analysis Report | GE Healthcare, Siemens H …
Cyclotron Market: Introduction
According to the report, the global cyclotron market was valued at US$ 215.5 Mn in 2019. It is projected to expand at a CAGR of ~3% from 2020 to 2030. Expansion activities of key radiopharma players; applications in clinical trials; increase in the geriatric population; pipeline assessment of new drugs; and disease indication mortality are major factors driving the cyclotron market. The shutdown of a few nuclear reactors has led to the…
